Undoubtedly, intratumor heterogeneity (ITH) is one of the causes of the intractability of cancers. Recently, technological innovation in genomics has promoted studies on ITH in solid tumors and on the pattern and level of diversity, which varies among malignancies. We profiled the genome in multiple regions of nine colorectal cancer (CRC) cases. The most impressive finding was that in the late phase, a parental clone branched into numerous subclones. We found that minor mutations were dominant in advanced CRC named neutral evolution; that is, driver gene aberrations were observed with high proportion in the early-acquired phase, but low in the lateacquired phase. Then, we validated that neutral evolution could cause ITH in advanced CRC by super-computational analysis. According to the clinical findings, we explored a branching evolutionary process model in cancer evolution, which assumes that each tumor cell has cellular automaton. According to the model, we (Table 1) . This multiregional analysis (MRA) sequencing approach enabled us not only to observe spatial heterogeneity, but also to calculate temporal alterations and eventually disclose the evolution of tumors. There are two types of somatic aberration in a tumor: ubiquitous aberrations (founder mutations, trunk mutations, or clonal mutations) and scattered aberrations (progressor mutations, branch/leaf mutations, or subclonal mutations). The former and the latter are triggered by a carcinogenic event and a late event, respectively.
| INTRODUCTION
In general, intratumor heterogeneity (ITH) is considered one of the critical causes of intractability in the treatment of cancers; therefore, it is very important to clarify the precise mechanism underlying ITH to establish a strategy for the treatment of solid cancers.
Recently, ITH-related studies have used next-generation sequencing to conduct whole-exome sequencing of multiple excised samples from primary and/or metastatic tumors and have comprehensively integrated whole sequence data (Table 1) . This multiregional analysis (MRA) sequencing approach enabled us not only to observe spatial heterogeneity, but also to calculate temporal alterations and eventually disclose the evolution of tumors. There are two types of somatic aberration in a tumor: ubiquitous aberrations (founder mutations, trunk mutations, or clonal mutations) and scattered aberrations (progressor mutations, branch/leaf mutations, or subclonal mutations). The former and the latter are triggered by a carcinogenic event and a late event, respectively.
In addition, we disclose the clinical significance of defining the clonality of genomic aberrations by the MRA method from the viewpoint of targeting the cancers. In the phylogenic tree of ITH in the study of cancer evolution, clonal mutations were located in the trunk, and minor mutations were in branches and leaves. According to Willyard et al, 34 to identify a bona-fide target in ITH providing sufficient antitumor effect, we should target any clonal events in the trunk for eliminating cancer.
In this review, we update the general information of ITH as fol- 
| Causative mechanism of ITH
There is a dispute between natural (Darwinian) selection and neutral evolution. In renal cell carcinoma, driver genes, such as mTOR, TSC1, PTEN, and PIK3CA, were observed at subclonal or parallel positions in an identical tumor. 31, 32 These alterations were considered to be a result of natural selection. On the contrary, progressor alterations accumulated in few driver genes, and the passenger mutations fostered neutral evolution.
According to the distribution of variant allele frequency (VAF), neutral evolution was observed in 30% of all malignancies. 41 Our previous wholeexome sequencing (WES) study by MRA showed neutral evolution in advanced CRC cases, which was validated by computational simulation analysis. According to our previous model, accumulation of non-driver genes, presence of cancer stem cells, and the microenvironment around cancer cells can foster neutral evolution in advanced CRC. 
| EVOLUTION MODEL AND CHRONOLOGICAL FACTORS TO FORM ITH
Our multiregional sequencing study showed that progressor mutations comprised 40% of all mutations, and most of them were classified as passenger mutations and form ITH. Neutral evolution along F I G U R E 1 Branching evolutionary process (BEP) model. A, A cell has n genes, d of which are driver genes. In a unit time step, a cell divides and dies with probabilities p and q, respectively. A cell division mutates each gene with a probability r. One driver mutation increases p by ffold. In this model, f indicates strength of the driver genes. B, Population entropy depends on parameters d and f. The division probability increases per driver mutation. Red area indicates negentropy or syntropy, whereas white area indicates entropy. C, Existence of strong driver genes leads to a homogenous tumor. D, Multiple driver genes of moderate strength generate intratumor heterogeneity with clonal evolution is a principal cause of ITH and fosters advanced CRC. 11 We simulated heterogeneous cancer evolution as 
| CLONAL SELECTIVE FACTORS FOR FOSTERING ITH

| Chemotherapy and treatment
According to the MRA of bladder cancer and ovarian cancer, there were several cases in which anticancer drugs and hormonal agents might determine the clones that survive. Treatment of cancer might be one of the selective pressures on clones, and recurrence might be derived from surviving clones. 7, 33 As depicted in Figure 2 , we implemented the simulation study to prove the presence of ITH with selective mutations in driver genes by exposing four environmental pressures, such as chemotherapy and other treatment modalities.
Existence of environmental selection can also enhance intratumor heterogeneity which is shaping the real heterogenous tumor.
| Anatomical microenvironment
In general, clones with diverse ITH acquired advantages for sustained survival. However, the cancer microenvironment, such as the blood flow, oxygen level, and anatomical structures, could be selective pressures for clones to survive. Considering the fate of cancer cells, a malignant cell will meet and surpass various pressures during cancer progression. According to a mouse model, recurrence of a primary tumor demands multiple propensities for each clone, such as invasion, local dissemination, vascular embolus, circulating tumor cells, and micrometastasis. 42 Therefore, ITH might provide advantages for metastasis.
| Cytokines in the microenvironment
Non-cell autonomous driving of tumor growth stabilizes subclonal heterogeneity, thereby enabling the survival of interclonal interactions. A xenograft model of chemokine-producing transgenic mouse-derived clones and parental clones was applied in a study by Marusyk et al. 43 In terms of the variability between the groups in morphology, proliferation, and vascularization, only chemokine (C-C motif) ligand 5 (CCL5)-and interleukin 11 (IL-11)-overexpressing subclones were able to enhance tumor growth. Tumor progression is frequently limited by microenvironmental constraints that cannot be overcome by the autonomous increase in cell proliferation rates.
Instead, progression depends on alterations of the microenvironment, accelerated by cytokines. 
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Clones carrying passenger mutations would senesce or die, such that the mutation would be lost from the catalog of variants seen in resected cancer specimens. This is negative or purifying selection, which leads to a dN/dS <1 in a given gene or set of genes, if it occurs at appreciable rates. [47] [48] [49] [50] If the negatively selected genes are 0.02%-0.5% of all genes, the dN/dS <1, and clones with coding mutations will be lost per tumor. On the contrary, some somatic mutations, such as driver genes, can confer a growth advantage, whereas others may impair cell survival or proliferation. Positively selected genes have a dN/dS ≥1 and were 1%-3.9% of all genes. There were 1-10 + driver mutations per tumor, and they had a much stronger force than negative selection.
According to the study by Martincorena et al, 50 CRC showed a relatively higher dN/dS ratio than other cancers. Therefore, the dN/dS ratio indicated that positively selected genes might exist under negative selection in advanced CRC. However, our previous study disclosed neutral evolution in advanced CRC with a number of minor (non-driver) mutations according to our multisampling and sequence data. 11 To comprehend this contradiction, we have provided the following possible explanation.
| Impaired neoantigen presentation by chromosomal aberration
Immune evasion is one of the hallmarks of cancer. Losing the ability to present neoantigens, as a result of human leukocyte antigen reported that HLA loss of heterozygosity (LOH) occurs in 40% of NSCLC. LOH is an immune escape mechanism that is subject to strong microenvironment later in tumor evolution. Subclonal LOH was observed on chromosome 6, which harbored HLA haplotypes, and the number of putative neoantigens presented to T cells was clearly impaired. 42 Therefore, cells with a high number of somatic mutations might not present neoantigens and evade the immune response.
In addition, compared with early CRC, copy number aberrations were specifically observed in advanced CRC (T. Saito, unpublished data). The number of somatic mutations on chromosomes was drastically altered, along with aneuploidy or chromosomal loss in advanced CRC. Many non-driver, passenger genes on the amplified chromosomes might not have been eliminated and were not affected by natural selection. Further studies will be required to prove it.
| FURTHER ANALYSIS OF ITH FOR CLINICAL APPLICATIONS
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